Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study

@article{Swerdlow2002RiskOC,
  title={Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study},
  author={A. J. Swerdlow and C D Higgins and Peter Adlard and Mary Anne Preece},
  journal={The Lancet},
  year={2002},
  volume={360},
  pages={273-277}
}
BACKGROUND Growth hormone raises serum concentrations of insulin-like growth factor IGF-I, which is mitogenic and antiapoptotic. There is evidence that raised endogenous levels of growth hormone and IGF-I might be associated with increased risk of certain solid cancers, but there have been no data on long-term risks of solid cancers after growth hormone treatment. METHODS We did a cohort study to investigate cancer incidence and mortality in 1848 patients in the UK who were treated during… Expand
Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study
TLDR
The results do not generally support a carcinogenic effect of r-hGH, but the unexplained trend in cancer mortality risk in relation to GH dose in patients with previous cancer, and the indication of possible effects on bone cancer, bladder cancer and HL risks, need further investigation. Expand
Cancer Risk Following Growth Hormone Use in Childhood
TLDR
There appears to be no increased risk for the development of leukaemia in those treated with GH unless there is an underlying predisposition, and subsequent GH use does not appear to increase the risk of tumour recurrence. Expand
Growth hormone treatment and risk of malignancy
TLDR
There is no clear evidence of a causal relationship between GH treatment and tumor development, but a small number of studies reported that childhood cancer survivors who receive GH treatment have a small increased risk of developing de novo cancer and secondary malignant neoplasm. Expand
Risk of cancer in patients treated with recombinant human growth hormone in childhood
  • S. Cianfarani
  • Medicine
  • Annals of pediatric endocrinology & metabolism
  • 2019
TLDR
The aim of this review is to critically review the data linking GH therapy during childhood with cancer risk, highlighting strengths and weaknesses of the available evidence. Expand
Growth hormone treatment and risk of malig
Growth hormone (GH) treatment has been increasingly widely used for children with GH deficiencies as the survival rate of pediatric patients with malignancies has increased. Both GH and insulin-likeExpand
Does growth hormone cause cancer?
TLDR
Given the experimental evidence that indicates GH/IGF‐1 provides an antiapoptotic environment that may favour survival of genetically damaged cells, longer‐term surveillance is necessary; over many years, even a subtle alteration in the environmental milieu in this direction, although not inducing cancer, could result in acceleration of carcinogenesis. Expand
Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone
TLDR
The SAGhE cohort is the largest and longest follow-up cohort study of growth hormone-treated patients with follow- up and analysis independent of industry and forms a major resource for investigating cancer and mortality risks in r-hGH patients. Expand
Growth hormone treatment and cancer risk.
TLDR
All children who have received GH, in particular cancer survivors and those receiving GH in adulthood, should be in surveillance programs to assess whether an increased rate of late-onset and rare tumours may occur. Expand
Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database).
TLDR
There is no evidence in this series that GH treatment in young patients with growth disorders results in an increased risk of developing cancer relative to that expected in the normal population. Expand
Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients.
TLDR
The death rate in pituitary-derived GH recipients was almost four times the expected rate, highlighting the importance of early intervention when infection occurs in patients with adrenal insufficiency, and aggressive treatment of panhypopituitarism. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Risk of leukemia after treatment with pituitary growth hormone.
TLDR
This cohort of growth hormone recipients had a significantly increased rate of leukemia compared with the age-, race- and gender-matched general population, and the upper bound CI of the relative risk in this population is well below the other estimates. Expand
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
TLDR
A positive relation between circulating IGF-I concentration and risk of breast cancer was found among premenopausal but not postmenopausal women, and may be useful in the identification of women at high risk of Breast cancer and in the development of risk reduction strategies. Expand
Risk of leukemia in children treated with human growth hormone: review and reanalysis.
TLDR
Excluding data on patients with known risk factors for leukemia provides a more accurate estimate of the risks in GH-treated patients, and the incidence of leukemia in these patients is comparable to that in the general population of age-matched children. Expand
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.
TLDR
Ass associations of plasma levels of IGF-I and IGFBP-3 with the risk of colorectal cancer are suggested to be consistent during the first and the second 7-year follow-up intervals and among younger and older men. Expand
Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3
TLDR
Ass associations of plasma levels of IGF-I and IGFBP-3 with the risk of colorectal cancer are suggested to be consistent during the first and the second 7-year follow-up intervals and among younger and older men. Expand
A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women.
  • E. Giovannucci, M. Pollak, +6 authors S. Hankinson
  • Medicine
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2000
TLDR
High levels of circulating IGF-1 and particularly low levels of IGFBP-3 are associated independently with an elevated risk of large or tubulovillous/villous colorectal adenoma and cancer. Expand
Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom.
TLDR
Recurrence or progression of intracranial tumours and potentially avoidable metabolic consequences of hypopituitarism were the main causes of death and growth hormone treatment probably did not contribute to new tumour development. Expand
Safety of growth hormone after treatment of a childhood malignancy.
TLDR
Despite the theoretical arguments, there is no evidence of an increased risk of tumour recurrence following GH therapy in replacement dosage in children previously treated for a malignancy. Expand
IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai
TLDR
It is suggested that circulating IGF-2 and IGFBP-3 can serve as early indicators of impending colorectal cancer. Expand
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
TLDR
A strong positive association was observed between IGF-I levels and prostate cancer risk, independent of baseline prostate-specific antigen levels, which may have implications for risk reduction and treatment. Expand
...
1
2
3
4
...